Erez Chimovits

Director

Erez Chimovits (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Braveheart Bio, Inc. (BRVE). Across 1 priced purchase filing, the average 21-session return was -10.0% from execution and +5.0% from disclosure (delay-adjusted; derived). The largest single filing was $34.9M of BRVE (1,940,000 sh across 2 lots, as filed), executed Aug 7.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

-10.0%

avg across 1 priced filings

Delay-adjustediThe same average, entered at disclosure dates

+5.0%

same 1 filings, from disclosure

Filings, ttm

1 buys · 0 sells

Median delay

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$34.9M

shares × price, as filed

Last traded

Aug 7

Filed Aug 11

Open performance→

Volume by month

Buys $48.9M Sells $0

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 1 filing

Sector per market data · by filing · past 12 months

Most traded names

BRVE

Braveheart Bio, Inc. BRVE · 1 buy · 0 sells 1 filing UPB UPB UPB · 1 buy · 0 sells 1 filing

Recent filings

BRVEPURCHASE Braveheart Bio, Inc. View filing → $34.9M
1,940,000 sh across 2 lots
Exec Aug 7
Filed Aug 11 · 5:31 PM ET UPBPURCHASE Upstream Bio, Inc. View filing → $14.0M
825,000 sh across 2 lots
Exec Oct 15 2024
Filed Oct 17 2024 · 5:30 PM ET